These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 23547755)

  • 1. Progress in structure-based design of EGFR inhibitors.
    Mitrasinovic PM
    Curr Drug Targets; 2013 Jun; 14(7):817-29. PubMed ID: 23547755
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers.
    Roskoski R
    Pharmacol Res; 2019 Jan; 139():395-411. PubMed ID: 30500458
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibitory activity against epidermal growth factor receptor (EGFR) based on single point mutations of active site residues.
    Mitrasinovic PM
    Med Chem; 2014 May; 10(3):252-70. PubMed ID: 23628078
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural elucidation of unique inhibitory activities of two thiazolo[ 4,5-d]pyrimidines against epidermal growth factor receptor (EGFR): implications for successful drug design.
    Mitrasinovic PM
    Med Chem; 2014; 10(1):46-58. PubMed ID: 23628079
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A review on progression of epidermal growth factor receptor (EGFR) inhibitors as an efficient approach in cancer targeted therapy.
    Ayati A; Moghimi S; Salarinejad S; Safavi M; Pouramiri B; Foroumadi A
    Bioorg Chem; 2020 Jun; 99():103811. PubMed ID: 32278207
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epidermal growth factor receptors: a functional perspective.
    Mitrasinovic PM
    Curr Radiopharm; 2012 Jan; 5(1):29-33. PubMed ID: 22074479
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel substituted quinazolines for potent EGFR tyrosine kinase inhibitors.
    Cruz-López O; Conejo-García A; Núñez MC; Kimatrai M; García-Rubiño ME; Morales F; Gómez-Pérez V; Campos JM
    Curr Med Chem; 2011; 18(7):943-63. PubMed ID: 21254978
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EGFR as a potential target for the treatment of pancreatic cancer: dilemma and controversies.
    Nedaeinia R; Avan A; Manian M; Salehi R; Ghayour-Mobarhan M
    Curr Drug Targets; 2014; 15(14):1293-301. PubMed ID: 25429712
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting ErbB receptors in high-grade glioma.
    Berezowska S; Schlegel J
    Curr Pharm Des; 2011; 17(23):2468-87. PubMed ID: 21827413
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rational design of potent and selective EGFR tyrosine kinase inhibitors as anticancer agents.
    Ghosh S; Liu XP; Zheng Y; Uckun FM
    Curr Cancer Drug Targets; 2001 Aug; 1(2):129-40. PubMed ID: 12188886
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined Treatment with Triptolide and Tyrosine Kinase Inhibitors Synergistically Enhances Apoptosis in Non-small Cell Lung Cancer H1975 Cells but Not H1299 Cells through EGFR/Akt Pathway.
    Tong X; Jiang P; Li Y; Guo L; Zhang HM; Zhang BK; Yan M
    Chem Pharm Bull (Tokyo); 2019 Aug; 67(8):864-871. PubMed ID: 31142691
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The ErbB/HER family of protein-tyrosine kinases and cancer.
    Roskoski R
    Pharmacol Res; 2014 Jan; 79():34-74. PubMed ID: 24269963
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Review on EGFR Inhibitors: Critical Updates.
    Singh D; Attri BK; Gill RK; Bariwal J
    Mini Rev Med Chem; 2016; 16(14):1134-66. PubMed ID: 26996617
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting the EGF/HER Ligand-Receptor System in Cancer.
    Esparís-Ogando A; Montero JC; Arribas J; Ocaña A; Pandiella A
    Curr Pharm Des; 2016; 22(39):5887-5898. PubMed ID: 27426127
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    Shi Z; Chen J; Guo X; Cheng L; Guo X; Yu T
    J Cancer Res Ther; 2018 Jan; 14(1):18-23. PubMed ID: 29516953
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structural and molecular insights from dual inhibitors of EGFR and VEGFR2 as a strategy to improve the efficacy of cancer therapy.
    Budipramana K; Sangande F
    Chem Biol Drug Des; 2024 May; 103(5):e14534. PubMed ID: 38697951
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epidermal growth factor receptor as a target for anti-cancer agent design.
    Cao J; Fang H; Wang B; Ma C; Xu W
    Anticancer Agents Med Chem; 2010 Jul; 10(6):491-503. PubMed ID: 20698825
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure-Based Drug Design Studies Toward the Discovery of Novel Chalcone Derivatives as Potential Epidermal Growth Factor Receptor (EGFR) Inhibitors.
    Al-Anazi M; Al-Najjar BO; Khairuddean M
    Molecules; 2018 Dec; 23(12):. PubMed ID: 30563058
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors from the natural origin: a recent perspective.
    Patel HM; Rane R; Thapliyal N; Palkar M; Shaikh M; Karpoormath R
    Anticancer Agents Med Chem; 2015; 15(8):988-1011. PubMed ID: 25763933
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of additional inhibition of human epidermal growth factor receptor 2 with the bispecific tyrosine kinase inhibitor AEE788 on the resistance to specific EGFR inhibition in glioma cells.
    Berezowska S; Diermeier-Daucher S; Brockhoff G; Busch R; Duyster J; Grosu AL; Schlegel J
    Int J Mol Med; 2010 Nov; 26(5):713-21. PubMed ID: 20878094
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.